KURA Stock Analysis: Kura Oncology | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 902m USD | 12M Return: -5.7% | US50127T1097 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 18.7M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Kura Oncology is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing cancer therapeutics. Its first commercial product, KOMZIFTI (ziftomenib), is an oral small molecule menin inhibitor, reflecting the companys emphasis on targeted, chemistry-based drug design rather than biologic therapies. The pipeline also includes darlifarnib, currently in a Phase 1 trial evaluating combination regimens in solid tumors, and KO-7246, a next-generation menin inhibitor being explored in diabetes and cardiometabolic disorders.
As a small-cap biotech, Kura operates within a sector characterized by lengthy R&D timelines, significant cash burn, and reliance on a mix of commercial revenue, partnerships, and capital markets to fund clinical development. Its expansion of the menin inhibitor franchise beyond oncology into cardiometabolic disease illustrates a strategy of leveraging a single mechanism across multiple therapeutic areas to broaden long-term commercial potential.
- KOMZIFTI commercial launch generates first product revenue stream
- Darlifarnib Phase 1 solid tumor combination data readouts near
- Syndax revumenib competition pressures menin inhibitor market share
| Net Income: -296.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.45 > 0.02 and ΔFCF/TA -20.19 > 1.0 |
| NWC/Revenue: 571.4% < 20% (prev 663.9%; Δ -92.54% < -1%) |
| CFO/TA -0.19 > 3% & CFO -111.8m > Net Income -296.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (88.9m) vs 12m ago 1.45% < -2% |
| Gross Margin: 94.13% > 18% (prev 99.24%; Δ -5.10% > 0.5%) |
| Asset Turnover: 12.16% > 50% (prev 12.20%; Δ -0.04% > 0%) |
| Interest Coverage Ratio: -208.2 > 6 (EBIT TTM -295.7m / Interest Expense TTM 1.42m) |
| A: 0.75 (Total Current Assets 559.4m - Total Current Liabilities 118.2m) / Total Assets 587.8m |
| B: -2.24 (Retained Earnings -1.32b / Total Assets 587.8m) |
| C: -0.47 (EBIT TTM -295.7m / Avg Total Assets 635.1m) |
| D: 0.09 (Book Value of Equity 48.4m / Total Liabilities 539.4m) |
| Altman-Z'' = -5.41 = D |
| DSRI: 2.23 (Receivables 9.45m/4.57m, Revenue 77.2m/83.3m) |
| GMI: 1.05 (GM 99.24% / 94.13%) |
| AQI: 1.51 (AQ_t 0.02 / AQ_t-1 0.02) |
| SGI: 0.93 (Revenue 77.2m / 83.3m) |
| TATA: -0.31 (NI -296.8m - CFO -111.8m) / TA 587.8m) |
| Beneish M = -1.75 (Cap -4..+1) = CCC |
As of October 16, 2026, the stock is trading at USD 9.70 with a total of 1,676,946 shares traded. Over the past week, the price has changed by -7.79%, over one month by -14.16%, over three months by -14.39% and over the past year by -5.73%.
Current recommended Stop Loss: 8.50 (which is 12.4% or 2.4 ATR below the current price).
Kura Oncology has received a consensus analysts rating of 4.69. Therefore, it is recommended to buy KURA.
- StrongBuy: 12
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 31.9 | 228.4% |
P/S = 11.6809
P/B = 20.2605
Revenue TTM = 77.2m USD
EBIT TTM = -295.7m USD
EBITDA TTM = -294.4m USD
Long Term Debt = 5.57m USD (from longTermDebt, last quarter)
Short Term Debt = 5.51m USD (from shortTermDebt, last quarter)
Debt = 39.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 14.7m
Net Debt = -33.8m USD (calculated: Debt 39.1m - CCE 72.9m)
Enterprise Value = 868.3m USD (902.1m + Debt 39.1m - CCE 72.9m)
Interest Coverage Ratio = -208.2 (Ebit TTM -295.7m / Interest Expense TTM 1.42m)
EV/FCF = -3.31x (Enterprise Value 868.3m / FCF TTM -262.2m)
FCF Yield = -30.20% (FCF TTM -262.2m / Enterprise Value 868.3m)
FCF Margin = -339.5% (FCF TTM -262.2m / Revenue TTM 77.2m)
Net Margin = -384.3% (Net Income TTM -296.8m / Revenue TTM 77.2m)
Gross Margin = 94.13% ((Revenue TTM 77.2m - Cost of Revenue TTM 4.53m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.48 (Enterprise Value 868.3m / Total Assets 587.8m)
Interest Expense / Debt = 3.63% (Interest Expense 1.42m / Debt 39.1m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -233.6m (EBIT -295.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.64 (Total Current Assets 559.4m / Total Current Liabilities 120.6m)
Debt / Equity = 0.81 (Debt 39.1m / totalStockholderEquity, last quarter 48.4m)
Debt / EBITDA = 0.11 (negative EBITDA) (Net Debt -33.8m / EBITDA -294.4m)
Debt / FCF = 0.13 (negative FCF - burning cash) (Net Debt -33.8m / FCF TTM -262.2m)
Total Stockholder Equity = 143.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -46.73% (Net Income -296.8m / Total Assets 587.8m)
RoE = -207.2% (Net Income TTM -296.8m / Total Stockholder Equity 143.2m)
RoCE = -198.7% (out of range, set to none) (EBIT -295.7m / Capital Employed (Equity 143.2m + L.T.Debt 5.57m))
RoIC = -49.57% (negative operating profit) (NOPAT -233.6m / Invested Capital 471.2m)
WACC = 9.31% (E(902.1m)/V(941.2m) * Re(9.59%) + D(39.1m)/V(941.2m) * Rd(3.63%) * (1-Tc(0.21)))
Discount Rate = 9.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.49 | Cagr: 2.58%
[DCF] Fair Price = unknown (Cash Flow -262.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.31 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.04 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.81 | Chg30d=+0.09% | Revisions=+70% | Analysts=10
EPS current Year (2026-12-31): EPS=-3.17 | Chg30d=-0.27% | Revisions=+70% | GrowthEPS=+0.2% | GrowthRev=+42.5%
EPS next Year (2027-12-31): EPS=-2.35 | Chg30d=-2.26% | Revisions=+70% | GrowthEPS=+26.0% | GrowthRev=+116.8%
[Analyst] Revisions Ratio: +88% (up=21, down=0)